MA50618A - Polyrhérapies et leurs utilisations - Google Patents

Polyrhérapies et leurs utilisations

Info

Publication number
MA50618A
MA50618A MA050618A MA50618A MA50618A MA 50618 A MA50618 A MA 50618A MA 050618 A MA050618 A MA 050618A MA 50618 A MA50618 A MA 50618A MA 50618 A MA50618 A MA 50618A
Authority
MA
Morocco
Prior art keywords
polyrherapies
Prior art date
Application number
MA050618A
Other languages
English (en)
Inventor
Keith W Mikule
Zebin Wang
Yinghui Zhou
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MA50618A publication Critical patent/MA50618A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA050618A 2017-10-06 2018-10-05 Polyrhérapies et leurs utilisations MA50618A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762569239P 2017-10-06 2017-10-06

Publications (1)

Publication Number Publication Date
MA50618A true MA50618A (fr) 2020-08-12

Family

ID=64051695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050618A MA50618A (fr) 2017-10-06 2018-10-05 Polyrhérapies et leurs utilisations

Country Status (17)

Country Link
US (1) US11801240B2 (fr)
EP (1) EP3691685A1 (fr)
JP (1) JP2020536869A (fr)
KR (1) KR20200067164A (fr)
CN (1) CN111182923A (fr)
AU (2) AU2018346688A1 (fr)
BR (1) BR112020006845A2 (fr)
CA (1) CA3076859A1 (fr)
CL (2) CL2020000907A1 (fr)
CO (1) CO2020005223A2 (fr)
EA (1) EA202090655A1 (fr)
IL (1) IL273510A (fr)
MA (1) MA50618A (fr)
MX (1) MX2020003799A (fr)
PH (1) PH12020550400A1 (fr)
SG (1) SG11202002499TA (fr)
WO (1) WO2019071123A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
WO2018200517A1 (fr) 2017-04-24 2018-11-01 Tesaro, Inc. Procédés de fabrication de niraparib
TW202444417A (zh) * 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (fr) 2017-09-30 2019-04-04 Tesaro, Inc. Polythérapies pour le traitement du cancer
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
MX2020005659A (es) * 2017-12-06 2020-08-20 Jiangsu Hengrui Medicine Co Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
EP3966782A2 (fr) 2019-05-06 2022-03-16 Tesaro, Inc. Procédés de caractérisation et méthodes de traitement d'un type de cancer à l'aide d'images de cancer
US20230123585A1 (en) * 2020-03-03 2023-04-20 The University Of Chicago Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors
CN112007042B (zh) * 2020-09-10 2023-02-21 中国医学科学院医学生物学研究所 阿糖胞苷与原癌蛋白c-FOS抑制剂在制备治疗白血病的产品中的应用
CN112316149A (zh) * 2020-11-11 2021-02-05 王海涛 一种治疗tp53突变的晚期难治性实体瘤的药物及应用
IL303103A (en) * 2020-11-27 2023-07-01 Snbioscience Inc A pharmaceutical composition that includes insoluble nanoparticles containing a camptothecin compound for the treatment of cancer and its combined treatment
KR20220085742A (ko) * 2020-12-15 2022-06-22 칸트사이언스 주식회사 암 환자에서 혈관 신생 억제 및 항암제 치료 효과 증대용 조성물
CN114748479B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物
WO2022152902A1 (fr) * 2021-01-18 2022-07-21 Active Biotech Ab Tasquinomod ou sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé dans le traitement du syndrome myélodysplasique
KR20230135075A (ko) * 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
CN115177621B (zh) * 2021-04-02 2023-09-01 上海市第一人民医院 Av-951在制备用于抑制或治疗甲状腺相关眼病的药物中的应用
CN113101288B (zh) * 2021-05-08 2026-03-31 中国人民解放军空军军医大学 一种协同增效治疗脊索瘤的组合药物及其用途
JP2025501572A (ja) * 2021-12-23 2025-01-22 ボストン サイエンティフィック メディカル デバイス リミテッド 化学塞栓用組成物とそれを使用する治療方法
CN116077643B (zh) * 2021-12-31 2025-02-11 成都金瑞基业生物科技有限公司 治疗和/或预防肺癌的联合用药物及应用
CN114712515A (zh) * 2022-03-30 2022-07-08 上海交通大学医学院附属瑞金医院 一种dll4抑制剂联合parp抑制剂在制备治疗卵巢癌药物中的应用
CN115177594B (zh) * 2022-07-04 2023-08-15 武汉大学中南医院 一种阿昔替尼药物制剂及其制备方法
CN117462687A (zh) * 2022-07-20 2024-01-30 清华大学 一种用于制备预防或治疗骨转移癌药物的组合物及其应用
CN115154589B (zh) * 2022-08-26 2024-04-09 山东大学 白藜芦醇联合成纤维细胞生长因子1在缓解蒽环类药物诱导的心脏及肝脏毒性中的应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059571T3 (es) 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
DE68915900T2 (de) 1988-09-01 1994-11-24 Childrens Medical Center Angiogenese hemmendes Mittel.
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009064738A2 (fr) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Traitement de cancer du sein avec un inhibiteur parp seul ou en combinaison avec des agents anti-tumoraux
EP2240466B1 (fr) 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Sels pharmaceutiquement acceptables de 2-{4-[(3s)-pipéridin-3-yl]phényl}-2h-indazole-7-carboxamide
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
AR075239A1 (es) 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso
EP3279215B1 (fr) 2009-11-24 2020-02-12 MedImmune Limited Agents de liaison ciblés contre b7-h1
WO2011153383A1 (fr) 2010-06-04 2011-12-08 Bipar Science, Inc. Procédés de traitement d'un cancer des ovaires récurrent et résistant au platine avec du 4-iodo-3-nitrobenzamide en combinaison avec un antimétabolite et un composé de platine.
EP3327148B1 (fr) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Procédés permettant la prédiction de l'état des gènes brca1 et brca2 dans une cellule cancereuse
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
CA2742342A1 (fr) 2011-02-12 2012-08-12 Baylor Research Institute Le statut a l'egard de l'expression de msh3 determine le degre de reponse des cellules cancereuses a un traitement chimiotherapeutique faisant intervenir des inhibiteurs de la parp et des medicaments a base de platine
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CA2867434C (fr) 2012-06-07 2021-10-12 Institut Curie Procede de detection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines
EP2928473B1 (fr) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Arylation n-2 régiosélective d'indazoles
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
WO2014138101A1 (fr) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Signature génique pour prédire un cancer déficient pour la recombinaison homologue (rh)
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA2931181C (fr) 2013-12-09 2023-01-24 Institut Curie Procede pour la detection de l'inactivation de voie de recombinaison homologue (brca1/2) dans des tumeurs humaines
JP6663350B2 (ja) 2014-01-16 2020-03-11 クロヴィス・オンコロジー，インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用
US20170175197A1 (en) 2014-01-29 2017-06-22 Caris Mpi, Inc. Molecular profiling of immune modulators
JP6648040B2 (ja) 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
WO2016176503A1 (fr) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Traitement du mélanome pd-l1 négatif à l'aide d'un anticorps anti-pd-1 et d'un anticorps anti-ctla-4
EP3303397A1 (fr) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Méthodes destinées à traiter le cancer à l'aide d'anticorps anti-ox40 et d'antagonistes se liant à l'axe pd-1
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
WO2017142871A1 (fr) 2016-02-15 2017-08-24 Astrazeneca Ab Procédés comprenant un dosage intermittent et fixe de cediranib
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
CN110049777A (zh) 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
EP3606523A1 (fr) 2017-03-27 2020-02-12 Tesaro, Inc. Formulations de niraparib
WO2018200517A1 (fr) 2017-04-24 2018-11-01 Tesaro, Inc. Procédés de fabrication de niraparib
TWI791519B (zh) 2017-04-27 2023-02-11 美商提薩羅有限公司 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
US20200129482A1 (en) 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (fr) 2017-09-30 2019-04-04 Tesaro, Inc. Polythérapies pour le traitement du cancer
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
TW201929902A (zh) 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
EA201992594A1 (ru) 2018-03-26 2020-03-20 Тесаро, Инк. Комбинированные терапии для лечения рака
US11970530B2 (en) 2020-08-13 2024-04-30 Astrazeneca Ab Methods of treating homologous recombination deficient cancer

Also Published As

Publication number Publication date
BR112020006845A2 (pt) 2020-10-06
CN111182923A (zh) 2020-05-19
AU2022201944A1 (en) 2022-04-14
SG11202002499TA (en) 2020-04-29
WO2019071123A1 (fr) 2019-04-11
EP3691685A1 (fr) 2020-08-12
US11801240B2 (en) 2023-10-31
EA202090655A1 (ru) 2020-12-07
MX2020003799A (es) 2020-11-06
KR20200067164A (ko) 2020-06-11
CL2020000907A1 (es) 2020-08-14
CL2020002958A1 (es) 2021-03-05
CA3076859A1 (fr) 2019-04-11
PH12020550400A1 (en) 2021-03-08
IL273510A (en) 2020-05-31
CO2020005223A2 (es) 2020-05-15
US20200306236A1 (en) 2020-10-01
AU2018346688A1 (en) 2020-04-23
JP2020536869A (ja) 2020-12-17

Similar Documents

Publication Publication Date Title
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3661563A4 (fr) Nanomatériaux biomimétiques et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3707100A4 (fr) Borures métalliques et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
EP3389658A4 (fr) Inhibiteurs de glycosidase et leurs utilisations
EP3902530A4 (fr) Nanovaccins polymères et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3624797A4 (fr) Inhibiteurs de kinase et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3478516A4 (fr) Structures multicouches et leurs utilisations
EP3893945A4 (fr) Esters cromoglycique et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3347020A4 (fr) Acétamide thiénotriazoldiazépines et leurs utilisations
EP3720434A4 (fr) Mélanges non racémiques et leurs utilisations